1. College of Biotechnology, Southwest University, Chongqing 400715, China 2. State Key Laboratory of Trauma, Burn and Combined Injury, Department of Stem Cell & Regenerative Medicine, Daping Hospital and Research Institute of Surgery, Chongqing 400042, China 3. Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing 100853, China
Chimeric antigen receptor (CAR) T cells have been indicated effective in treating B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma and have shown encouraging results in preclinical and clinical studies. However, CAR T cells have achieved minimal success against solid malignancies because of the additional obstacles of their insufficient migration into tumors and poor amplification and persistence, in addition to antigen-negative relapse and an immunosuppressive microenvironment. Various preclinical studies are exploring strategies to overcome the above challenges. Mobilization of endogenous immune cells is also necessary for CAR T cells to obtain their optimal therapeutic effect given the importance of the innate immune responses in the elimination of malignant tumors. In this review, we focus on the recent advances in the engineering of CAR T cell therapies to restore the immune response in solid malignancies, especially with CAR T cells acting as cellular carriers to deliver immunomodulators to tumors to mobilize the endogenous immune response. We also explored the sensitizing effects of conventional treatment approaches, such as chemotherapy and radiotherapy, on CAR T cell therapy. Finally, we discuss the combination of CAR T cells with biomaterials or oncolytic viruses to enhance the anti-tumor outcomes of CAR T cell therapies in solid tumors.
G Ding, H Chen. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches. Sci China Life Sci 2016; 59(7): 673–677 https://doi.org/10.1007/s11427-016-0017-3
pmid: 27142351
G Wei, L Ding, J Wang, Y Hu, H Huang. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. Exp Hematol Oncol 2017; 6(1): 10 https://doi.org/10.1186/s40164-017-0070-9
pmid: 28413717
6
S Yu, A Li, Q Liu, T Li, X Yuan, X Han, K Wu. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol 2017; 10(1): 78 https://doi.org/10.1186/s13045-017-0444-9
pmid: 28356156
7
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR Verneris, HE Stefanski, GD Myers, M Qayed, B De Moerloose, H Hiramatsu, K Schlis, KL Davis, PL Martin, ER Nemecek, GA Yanik, C Peters, A Baruchel, N Boissel, F Mechinaud, A Balduzzi, J Krueger, CH June, BL Levine, P Wood, T Taran, M Leung, KT Mueller, Y Zhang, K Sen, D Lebwohl, MA Pulsipher, SA Grupp. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378(5): 439–448 https://doi.org/10.1056/NEJMoa1709866
pmid: 29385370
8
SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, U Jäger, S Jaglowski, C Andreadis, JR Westin, I Fleury, V Bachanova, SR Foley, PJ Ho, S Mielke, JM Magenau, H Holte, S Pantano, LB Pacaud, R Awasthi, J Chu, Ö Anak, G Salles, RT Maziarz; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380(1): 45–56 https://doi.org/10.1056/NEJMoa1804980
pmid: 30501490
9
SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, I Braunschweig, OO Oluwole, T Siddiqi, Y Lin, JM Timmerman, PJ Stiff, JW Friedberg, IW Flinn, A Goy, BT Hill, MR Smith, A Deol, U Farooq, P McSweeney, J Munoz, I Avivi, JE Castro, JR Westin, JC Chavez, A Ghobadi, KV Komanduri, R Levy, ED Jacobsen, TE Witzig, P Reagan, A Bot, J Rossi, L Navale, Y Jiang, J Aycock, M Elias, D Chang, J Wiezorek, WY Go. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377(26): 2531–2544 https://doi.org/10.1056/NEJMoa1707447
pmid: 29226797
10
E Zah, MY Lin, A Silva-Benedict, MC Jensen, YY Chen. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 2016; 4(6): 498–508 https://doi.org/10.1158/2326-6066.CIR-15-0231
pmid: 27059623
11
Z Grada, M Hegde, T Byrd, DR Shaffer, A Ghazi, VS Brawley, A Corder, K Schönfeld, J Koch, G Dotti, HE Heslop, S Gottschalk, WS Wels, ML Baker, N Ahmed. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013; 2: e105 https://doi.org/10.1038/mtna.2013.32
pmid: 23839099
12
M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, J Perazzelli, M Klichinsky, V Aikawa, F Nazimuddin, M Kozlowski, J Scholler, SF Lacey, JJ Melenhorst, JJ Morrissette, DA Christian, CA Hunter, M Kalos, DL Porter, CH June, SA Grupp, S Gill. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 2016; 126(10): 3814–3826 https://doi.org/10.1172/JCI87366
pmid: 27571406
13
K Bielamowicz, K Fousek, TT Byrd, H Samaha, M Mukherjee, N Aware, MF Wu, JS Orange, P Sumazin, TK Man, SK Joseph, M Hegde, N Ahmed. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro-oncol 2018; 20(4): 506–518 https://doi.org/10.1093/neuonc/nox182
pmid: 29016929
14
KC Straathof, MA Pulè, P Yotnda, G Dotti, EF Vanin, MK Brenner, HE Heslop, DM Spencer, CM Rooney. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105(11): 4247–4254 https://doi.org/10.1182/blood-2004-11-4564
pmid: 15728125
15
A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, K Straathof, E Liu, AG Durett, B Grilley, H Liu, CR Cruz, B Savoldo, AP Gee, J Schindler, RA Krance, HE Heslop, DM Spencer, CM Rooney, MK Brenner. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365(18): 1673–1683 https://doi.org/10.1056/NEJMoa1106152
pmid: 22047558
I Diaconu, B Ballard, M Zhang, Y Chen, J West, G Dotti, B Savoldo. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol Ther 2017; 25(3): 580–592 https://doi.org/10.1016/j.ymthe.2017.01.011
pmid: 28187946
18
SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, JJ Morrissette, J Scholler, D Song, DL Porter, M Carroll, CH June, S Gill. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015; 29(8): 1637–1647 https://doi.org/10.1038/leu.2015.52
pmid: 25721896
19
GL Beatty, AR Haas, MV Maus, DA Torigian, MC Soulen, G Plesa, A Chew, Y Zhao, BL Levine, SM Albelda, M Kalos, CH June. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2(2): 112–120 https://doi.org/10.1158/2326-6066.CIR-13-0170
pmid: 24579088
20
SC Katz, RA Burga, E McCormack, LJ Wang, W Mooring, GR Point, PD Khare, M Thorn, Q Ma, BF Stainken, EO Assanah, R Davies, NJ Espat, RP Junghans. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015; 21(14): 3149–3159 https://doi.org/10.1158/1078-0432.CCR-14-1421
pmid: 25850950
21
J Tchou, Y Zhao, BL Levine, PJ Zhang, MM Davis, JJ Melenhorst, I Kulikovskaya, AL Brennan, X Liu, SF Lacey, AD Posey Jr, AD Williams, A So, JR Conejo-Garcia, G Plesa, RM Young, S McGettigan, J Campbell, RH Pierce, JM Matro, AM DeMichele, AS Clark, LJ Cooper, LM Schuchter, RH Vonderheide, CH June. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 2017; 5(12): 1152–1161 https://doi.org/10.1158/2326-6066.CIR-17-0189
pmid: 29109077
22
MC van Schalkwyk, SE Papa, JP Jeannon, T Guerrero Urbano, JF Spicer, J Maher. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 2013; 24(3): 134–142 https://doi.org/10.1089/humc.2013.144
pmid: 24099518
23
H Harlin, Y Meng, AC Peterson, Y Zha, M Tretiakova, C Slingluff, M McKee, TF Gajewski. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69(7): 3077–3085 https://doi.org/10.1158/0008-5472.CAN-08-2281
pmid: 19293190
24
L Cherkassky, A Morello, J Villena-Vargas, Y Feng, DS Dimitrov, DR Jones, M Sadelain, PS Adusumilli. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 2016; 126(8): 3130–3144 https://doi.org/10.1172/JCI83092
pmid: 27454297
25
TF Gajewski, Y Meng, C Blank, I Brown, A Kacha, J Kline, H Harlin. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213(1): 131–145 https://doi.org/10.1111/j.1600-065X.2006.00442.x
pmid: 16972901
26
MH Kershaw, C Devaud, LB John, JA Westwood, PK Darcy. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. OncoImmunology 2013; 2(9): e25962 https://doi.org/10.4161/onci.25962
pmid: 24327938
27
SJ Turley, V Cremasco, JL Astarita. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 2015; 15(11): 669–682 https://doi.org/10.1038/nri3902
pmid: 26471778
28
GT Motz, SP Santoro, LP Wang, T Garrabrant, RR Lastra, IS Hagemann, P Lal, MD Feldman, F Benencia, G Coukos. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20(6): 607–615 https://doi.org/10.1038/nm.3541
pmid: 24793239
JP Leonard, ML Sherman, GL Fisher, LJ Buchanan, G Larsen, MB Atkins, JA Sosman, JP Dutcher, NJ Vogelzang, JL Ryan. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997; 90(7): 2541–2548
pmid: 9326219
31
D Chinnasamy, Z Yu, SP Kerkar, L Zhang, RA Morgan, NP Restifo, SA Rosenberg. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18(6): 1672–1683 https://doi.org/10.1158/1078-0432.CCR-11-3050
pmid: 22291136
32
HJ Pegram, TJ Purdon, DG van Leeuwen, KJ Curran, SA Giralt, JN Barker, RJ Brentjens. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 2015; 29(2): 415–422 https://doi.org/10.1038/leu.2014.215
pmid: 25005243
33
V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, HE Heslop, CM Rooney, MK Brenner, G Dotti. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24(6): 1160–1170 https://doi.org/10.1038/leu.2010.75
pmid: 20428207
34
M Chmielewski, H Abken. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Reports 2017; 21(11): 3205–3219 https://doi.org/10.1016/j.celrep.2017.11.063
pmid: 29241547
35
H Tang, Y Wang, LK Chlewicki, Y Zhang, J Guo, W Liang, J Wang, X Wang, YX Fu. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 29(3): 285–296 https://doi.org/10.1016/j.ccell.2016.02.004
pmid: 26977880
36
L Zhang, SP Kerkar, Z Yu, Z Zheng, S Yang, NP Restifo, SA Rosenberg, RA Morgan. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011; 19(4): 751–759 https://doi.org/10.1038/mt.2010.313
pmid: 21285960
HJ Wagner, CM Bollard, S Vigouroux, MH Huls, R Anderson, HG Prentice, MK Brenner, HE Heslop, CM Rooney. A strategy for treatment of Epstein–arr virus-positive Hodgkin’s disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004; 11(2): 81–91 https://doi.org/10.1038/sj.cgt.7700664
pmid: 14685154
39
HJ Pegram, JC Lee, EG Hayman, GH Imperato, TF Tedder, M Sadelain, RJ Brentjens. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119(18): 4133–4141 https://doi.org/10.1182/blood-2011-12-400044
pmid: 22354001
40
M Chmielewski, AA Hombach, H Abken. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014; 257(1): 83–90 https://doi.org/10.1111/imr.12125
pmid: 24329791
41
M Chmielewski, C Kopecky, AA Hombach, H Abken. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011; 71(17): 5697–5706 https://doi.org/10.1158/0008-5472.CAN-11-0103
pmid: 21742772
42
M Koneru, TJ Purdon, D Spriggs, S Koneru, RJ Brentjens. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. OncoImmunology 2015; 4(3): e994446 https://doi.org/10.4161/2162402X.2014.994446
pmid: 25949921
43
M Koneru, R O’Cearbhaill, S Pendharkar, DR Spriggs, RJ Brentjens. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015; 13(1): 102 https://doi.org/10.1186/s12967-015-0460-x
pmid: 25890361
44
Y Liu, S Di, B Shi, H Zhang, Y Wang, X Wu, H Luo, H Wang, Z Li, H Jiang. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J Immunol 2019; 203(1): 198–207 https://doi.org/10.4049/jimmunol.1800033
pmid: 31142602
45
LV Hurton, H Singh, AM Najjar, KC Switzer, T Mi, S Maiti, S Olivares, B Rabinovich, H Huls, MA Forget, V Datar, P Kebriaei, DA Lee, RE Champlin, LJ Cooper. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA 2016; 113(48): E7788–E7797 https://doi.org/10.1073/pnas.1610544113
pmid: 27849617
46
RM Teague, BD Sather, JA Sacks, MZ Huang, ML Dossett, J Morimoto, X Tan, SE Sutton, MP Cooke, C Ohlén, PD Greenberg. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006; 12(3): 335–341 https://doi.org/10.1038/nm1359
pmid: 16474399
47
J Marks-Konczalik, S Dubois, JM Losi, H Sabzevari, N Yamada, L Feigenbaum, TA Waldmann, Y Tagaya. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 2000; 97(21): 11445–11450 https://doi.org/10.1073/pnas.200363097
pmid: 11016962
48
CA Klebanoff, SE Finkelstein, DR Surman, MK Lichtman, L Gattinoni, MR Theoret, N Grewal, PJ Spiess, PA Antony, DC Palmer, Y Tagaya, SA Rosenberg, TA Waldmann, NP Restifo. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101(7): 1969–1974 https://doi.org/10.1073/pnas.0307298101
pmid: 14762166
49
B Mlecnik, G Bindea, HK Angell, MS Sasso, AC Obenauf, T Fredriksen, L Lafontaine, AM Bilocq, A Kirilovsky, M Tosolini, M Waldner, A Berger, WH Fridman, A Rafii, V Valge-Archer, F Pagès, MR Speicher, J Galon. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 2014; 6(228): 228ra37 https://doi.org/10.1126/scitranslmed.3007240
pmid: 24648340
50
S Dadi, S Chhangawala, BM Whitlock, RA Franklin, CT Luo, SA Oh, A Toure, Y Pritykin, M Huse, CS Leslie, MO Li. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 2016; 164(3): 365–377 https://doi.org/10.1016/j.cell.2016.01.002
pmid: 26806130
C Hsu, MS Hughes, Z Zheng, RB Bray, SA Rosenberg, RA Morgan. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175(11): 7226–7234 https://doi.org/10.4049/jimmunol.175.11.7226
pmid: 16301627
53
G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, S Gottschalk. Transgenic expression of IL15 improves antiglioma activity of IL13Ra2-CAR T cells but results in antigen loss variants. Cancer Immunol Res 2017; 5(7): 571–581 https://doi.org/10.1158/2326-6066.CIR-16-0376
pmid: 28550091
54
G Baldassarre, M Fedele, S Battista, A Vecchione, AJ Klein-Szanto, M Santoro, TA Waldmann, N Azimi, CM Croce, A Fusco. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci USA 2001; 98(14): 7970–7975 https://doi.org/10.1073/pnas.141224998
pmid: 11427729
55
C Badoual, G Bouchaud, NH Agueznay, E Mortier, S Hans, A Gey, F Fernani, S Peyrard, PL -Puig, P Bruneval, X Sastre, A Plet, L Garrigue-Antar, F Quintin-Colonna, WH Fridman, D Brasnu, Y Jacques, E Tartour. The soluble a chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008; 68(10): 3907–3914 https://doi.org/10.1158/0008-5472.CAN-07-6842
pmid: 18483276
MJ Robertson, JM Kirkwood, TF Logan, KM Koch, S Kathman, LC Kirby, WN Bell, LM Thurmond, J Weisenbach, MM Dar. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 2008; 14(11): 3462–3469 https://doi.org/10.1158/1078-0432.CCR-07-4740
pmid: 18519778
58
LS Schwartzberg, I Petak, C Stewart, PK Turner, J Ashley, DM Tillman, L Douglas, M Tan, C Billups, R Mihalik, A Weir, K Tauer, S Shope, JA Houghton. Modulation of the Fas signaling pathway by IFN-γ in therapy of colon cancer: phase I trial and correlative studies of IFN-γ, 5-fluorouracil, and leucovorin. Clin Cancer Res 2002; 8(8): 2488–2498
pmid: 12171874
59
B Hu, J Ren, Y Luo, B Keith, RM Young, J Scholler, Y Zhao, CH June. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep 2017; 20(13): 3025–3033 https://doi.org/10.1016/j.celrep.2017.09.002
pmid: 28954221
60
MP Avanzi, O Yeku, X Li, DP Wijewarnasuriya, DG van Leeuwen, K Cheung, H Park, TJ Purdon, AF Daniyan, MH Spitzer, RJ Brentjens. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep 2018; 23(7): 2130–2141 https://doi.org/10.1016/j.celrep.2018.04.051
pmid: 29768210
61
J Kwoczek, SB Riese, S Tischer, S Bak, J Lahrberg, M Oelke, H Maul, R Blasczyk, M Sauer, B Eiz-Vesper. Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype. Transfusion 2018; 58(1): 88–99 https://doi.org/10.1111/trf.14365
pmid: 29023759
62
T Shum, B Omer, H Tashiro, RL Kruse, DL Wagner, K Parikh, Z Yi, T Sauer, D Liu, R Parihar, P Castillo, H Liu, MK Brenner, LS Metelitsa, S Gottschalk, CM Rooney. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 2017; 7(11): 1238–1247 https://doi.org/10.1158/2159-8290.CD-17-0538
pmid: 28830878
63
JC Markley, M Sadelain. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115(17): 3508–3519 https://doi.org/10.1182/blood-2009-09-241398
pmid: 20190192
64
S Stoiber, BL Cadilha, MR Benmebarek, S Lesch, S Endres, S Kobold. Limitations in the design of chimeric antigen receptors for cancer therapy. Cells 2019; 8(5): E472 https://doi.org/10.3390/cells8050472
pmid: 31108883
65
OO Yeku, TJ Purdon, M Koneru, D Spriggs, RJ Brentjens. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 2017; 7(1): 10541 https://doi.org/10.1038/s41598-017-10940-8
pmid: 28874817
66
M Martinez, EK Moon. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 2019; 10: 128 https://doi.org/10.3389/fimmu.2019.00128
pmid: 30804938
67
S Mardiana, BJ Solomon, PK Darcy, PA Beavis. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci Transl Med 2019; 11(495): eaaw2293 https://doi.org/10.1126/scitranslmed.aaw2293
pmid: 31167925
68
I Siddiqui, M Erreni, M van Brakel, R Debets, P Allavena. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer 2016; 4(1): 21 https://doi.org/10.1186/s40425-016-0125-1
pmid: 27096098
69
MH Kershaw, G Wang, JA Westwood, RK Pachynski, HL Tiffany, FM Marincola, E Wang, HA Young, PM Murphy, P Hwu. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002; 13(16): 1971–1980 https://doi.org/10.1089/10430340260355374
pmid: 12427307
JA Craddock, A Lu, A Bear, M Pule, MK Brenner, CM Rooney, AE Foster. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010; 33(8): 780–788 https://doi.org/10.1097/CJI.0b013e3181ee6675
pmid: 20842059
72
EK Moon, C Carpenito, J Sun, LC Wang, V Kapoor, J Predina, DJ Powell Jr, JL Riley, CH June, SM Albelda. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011; 17(14): 4719–4730 https://doi.org/10.1158/1078-0432.CCR-11-0351
pmid: 21610146
73
Y Xu, YM Hyun, K Lim, H Lee, RJ Cummings, SA Gerber, S Bae, TY Cho, EM Lord, M Kim. Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci USA 2014; 111(17): 6371–6376 https://doi.org/10.1073/pnas.1319296111
pmid: 24733886
74
W Peng, Y Ye, BA Rabinovich, C Liu, Y Lou, M Zhang, M Whittington, Y Yang, WW Overwijk, G Lizée, P Hwu. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16(22): 5458–5468 https://doi.org/10.1158/1078-0432.CCR-10-0712
pmid: 20889916
75
HD Hickman, GV Reynoso, BF Ngudiankama, SS Cush, J Gibbs, JR Bennink, JW Yewdell. CXCR3 chemokine receptor enables local CD8+ T cell migration for the destruction of virus-infected cells. Immunity 2015; 42(3): 524–537 https://doi.org/10.1016/j.immuni.2015.02.009
pmid: 25769612
76
H Asai, H Fujiwara, J An, T Ochi, Y Miyazaki, K Nagai, S Okamoto, J Mineno, K Kuzushima, H Shiku, H Inoue, M Yasukawa. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One 2013; 8(2): e56820 https://doi.org/10.1371/journal.pone.0056820
pmid: 23441216
77
N Müller, S Michen, S Tietze, K Töpfer, A Schulte, K Lamszus, M Schmitz, G Schackert, I Pastan, A Temme. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1a-secreting glioblastoma. J Immunother 2015; 38(5): 197–210 https://doi.org/10.1097/CJI.0000000000000082
pmid: 25962108
78
A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, AE Foster, HE Heslop, MK Brenner, G Dotti, B Savoldo. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113(25): 6392–6402 https://doi.org/10.1182/blood-2009-03-209650
pmid: 19377047
79
LM Whilding, L Halim, B Draper, AC Parente-Pereira, T Zabinski, DM Davies, J Maher. CAR T-cells targeting the integrin avb6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel) 2019; 11(5): E674 https://doi.org/10.3390/cancers11050674
pmid: 31091832
80
CP Duong, CS Yong, MH Kershaw, CY Slaney, PK Darcy. Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic. Mol Immunol 2015; 67(2 Pt A): 46–57 https://doi.org/10.1016/j.molimm.2014.12.009
pmid: 25595028
81
A Kunert, T Straetemans, C Govers, C Lamers, R Mathijssen, S Sleijfer, R Debets. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol 2013; 4: 363 https://doi.org/10.3389/fimmu.2013.00363
pmid: 24265631
82
I Melero, A Rouzaut, GT Motz, G Coukos. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014; 4(5): 522–526 https://doi.org/10.1158/2159-8290.CD-13-0985
pmid: 24795012
83
ST Kim, H Jeong, OH Woo, JH Seo, A Kim, ES Lee, SW Shin, YH Kim, JS Kim, KH Park. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 2013; 36(3): 224–231 https://doi.org/10.1097/COC.0b013e3182467d90
pmid: 22495453
84
J Galon, A Costes, F Sanchez-Cabo, A Kirilovsky, B Mlecnik, C Lagorce-Pagès, M Tosolini, M Camus, A Berger, P Wind, F Zinzindohoué, P Bruneval, PH Cugnenc, Z Trajanoski, WH Fridman, F Pagès. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795): 1960–1964 https://doi.org/10.1126/science.1129139
pmid: 17008531
85
K Adachi, Y Kano, T Nagai, N Okuyama, Y Sakoda, K Tamada. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 2018; 36(4): 346–351 https://doi.org/10.1038/nbt.4086
pmid: 29505028
86
DN Mauri, R Ebner, RI Montgomery, KD Kochel, TC Cheung, GL Yu, S Ruben, M Murphy, RJ Eisenberg, GH Cohen, PG Spear, CF Ware. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 1998; 8(1): 21–30 https://doi.org/10.1016/S1074-7613(00)80455-0
pmid: 9462508
87
K Tamada, K Shimozaki, AI Chapoval, Y Zhai, J Su, SF Chen, SL Hsieh, S Nagata, J Ni, L Chen. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000; 164(8): 4105–4110 https://doi.org/10.4049/jimmunol.164.8.4105
pmid: 10754304
88
Y Morel, JM Schiano de Colella, J Harrop, KC Deen, SD Holmes, TA Wattam, SS Khandekar, A Truneh, RW Sweet, JA Gastaut, D Olive, RT Costello. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000; 165(8): 4397–4404 https://doi.org/10.4049/jimmunol.165.8.4397
pmid: 11035077
P Yu, Y Lee, W Liu, RK Chin, J Wang, Y Wang, A Schietinger, M Philip, H Schreiber, YX Fu. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5(2): 141–149 https://doi.org/10.1038/ni1029
pmid: 14704792
94
P Yu, Y Lee, Y Wang, X Liu, S Auh, TF Gajewski, H Schreiber, Z You, C Kaynor, X Wang, YX Fu. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007; 179(3): 1960–1968 https://doi.org/10.4049/jimmunol.179.3.1960
pmid: 17641063
95
H Tang, Y Wang, LK Chlewicki, Y Zhang, J Guo, W Liang, J Wang, X Wang, YX Fu. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 30(3): 500 https://doi.org/10.1016/j.ccell.2016.08.011
pmid: 27622338
96
RJ Armitage, WC Fanslow, L Strockbine, TA Sato, KN Clifford, BM Macduff, DM Anderson, SD Gimpel, T Davis-Smith, CR Maliszewski, EA Clark, CA Smith, KH Grabstein, D Cosman, MK Spriggs. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357(6373): 80–82 https://doi.org/10.1038/357080a0
pmid: 1374165
97
M Armant, R Armitage, N Boiani, G Delespesse, M Sarfati. Functional CD40 ligand expression on T lymphocytes in the absence of T cell receptor engagement: involvement in interleukin-2-induced interleukin-12 and interferon-gamma production. Eur J Immunol 1996; 26(7): 1430–1434 https://doi.org/10.1002/eji.1830260705
pmid: 8766543
98
R Bhadra, JP Gigley, IA Khan. Cutting edge: CD40-CD40 ligand pathway plays a critical CD8-intrinsic and-extrinsic role during rescue of exhausted CD8 T cells. J Immunol 2011; 187(9): 4421–4425 https://doi.org/10.4049/jimmunol.1102319
pmid: 21949017
99
C Bourgeois, B Rocha, C Tanchot. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297(5589): 2060–2063 https://doi.org/10.1126/science.1072615
pmid: 12242444
100
M Frentsch, R Stark, N Matzmohr, S Meier, S Durlanik, AR Schulz, U Stervbo, K Jürchott, F Gebhardt, G Heine, MA Reuter, MR Betts, D Busch, A Thiel. CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood 2013; 122(3): 405–412 https://doi.org/10.1182/blood-2013-02-483586
pmid: 23719298
101
Y Liu, M Qureshi, J Xiang. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Cancer Biother Radiopharm 2002; 17(1): 11–18 https://doi.org/10.1089/10849780252824028
pmid: 11915168
102
Y Liu, D Xia, F Li, C Zheng, J Xiang. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005; 12(2): 122–132 https://doi.org/10.1038/sj.cgt.7700757
pmid: 15565183
T Elmetwali, LS Young, DH Palmer. CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol 2010; 184(2): 1111–1120 https://doi.org/10.4049/jimmunol.0900528
pmid: 20008286
105
A Angelou, E Antoniou, N Garmpis, C Damaskos, S Theocharis, GA Margonis. The role of soluble CD40L ligand in human carcinogenesis. Anticancer Res 2018; 38(5): 3199–3201
pmid: 29715163
106
K Kato, MJ Cantwell, S Sharma, TJ Kipps. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101(5): 1133–1141 https://doi.org/10.1172/JCI1472
pmid: 9486984
RH Vonderheide, JM Burg, R Mick, JA Trosko, D Li, MN Shaik, AW Tolcher, O Hamid. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. OncoImmunology 2013; 2(1): e23033 https://doi.org/10.4161/onci.23033
pmid: 23483678
109
GL Beatty, EG Chiorean, MP Fishman, B Saboury, UR Teitelbaum, W Sun, RD Huhn, W Song, D Li, LL Sharp, DA Torigian, PJ O’Dwyer, RH Vonderheide. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331(6024): 1612–1616 https://doi.org/10.1126/science.1198443
pmid: 21436454
WG Wierda, JE Castro, R Aguillon, D Sampath, A Jalayer, J McMannis, CE Prussak, M Keating, TJ Kipps. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010; 24(11): 1893–1900 https://doi.org/10.1038/leu.2010.191
pmid: 20882050
112
JE Castro, J Melo-Cardenas, M Urquiza, JS Barajas-Gamboa, RS Pakbaz, TJ Kipps. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res 2012; 72(12): 2937–2948 https://doi.org/10.1158/0008-5472.CAN-11-3368
pmid: 22505652
113
KJ Curran, BA Seinstra, Y Nikhamin, R Yeh, Y Usachenko, DG van Leeuwen, T Purdon, HJ Pegram, RJ Brentjens. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 2015; 23(4): 769–778 https://doi.org/10.1038/mt.2015.4
pmid: 25582824
114
NF Kuhn, TJ Purdon, DG van Leeuwen, AV Lopez, KJ Curran, AF Daniyan, RJ Brentjens. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 2019; 35(3): 473–488.e6 https://doi.org/10.1016/j.ccell.2019.02.006
115
B Heyman, Y Yang. Chimeric antigen receptor T cell therapy for solid tumors: current status, obstacles and future strategies. Cancers (Basel) 2019; 11(2): E191 https://doi.org/10.3390/cancers11020191
pmid: 30736355
116
DH Yoon, MJ Osborn, J Tolar, CJ Kim. Incorporation of immune checkpoint blockade into chimeric antigen receptor T clls (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci 2018; 19(2): E340 https://doi.org/10.3390/ijms19020340
pmid: 29364163
117
J Brahmer, KL Reckamp, P Baas, L Crinò, WE Eberhardt, E Poddubskaya, S Antonia, A Pluzanski, EE Vokes, E Holgado, D Waterhouse, N Ready, J Gainor, O Arén Frontera, L Havel, M Steins, MC Garassino, JG Aerts, M Domine, L Paz-Ares, M Reck, C Baudelet, CT Harbison, B Lestini, DR Spigel. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123–135 https://doi.org/10.1056/NEJMoa1504627
pmid: 26028407
118
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, D Schadendorf, R Dummer, M Smylie, P Rutkowski, PF Ferrucci, A Hill, J Wagstaff, MS Carlino, JB Haanen, M Maio, I Marquez-Rodas, GA McArthur, PA Ascierto, GV Long, MK Callahan, MA Postow, K Grossmann, M Sznol, B Dreno, L Bastholt, A Yang, LM Rollin, C Horak, FS Hodi, JD Wolchok. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23–34 https://doi.org/10.1056/NEJMoa1504030
pmid: 26027431
119
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, SS Tykodi, JA Sosman, G Procopio, ER Plimack, D Castellano, TK Choueiri, H Gurney, F Donskov, P Bono, J Wagstaff, TC Gauler, T Ueda, Y Tomita, FA Schutz, C Kollmannsberger, J Larkin, A Ravaud, JS Simon, LA Xu, IM Waxman, P Sharma; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803–1813 https://doi.org/10.1056/NEJMoa1510665
pmid: 26406148
120
JN Kochenderfer, ME Dudley, SH Kassim, RP Somerville, RO Carpenter, M Stetler-Stevenson, JC Yang, GQ Phan, MS Hughes, RM Sherry, M Raffeld, S Feldman, L Lu, YF Li, LT Ngo, A Goy, T Feldman, DE Spaner, ML Wang, CC Chen, SM Kranick, A Nath, DA Nathan, KE Morton, MA Toomey, SA Rosenberg. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33(6): 540–549 https://doi.org/10.1200/JCO.2014.56.2025
pmid: 25154820
121
JN Brudno, RP Somerville, V Shi, JJ Rose, DC Halverson, DH Fowler, JC Gea-Banacloche, SZ Pavletic, DD Hickstein, TL Lu, SA Feldman, AT Iwamoto, R Kurlander, I Maric, A Goy, BG Hansen, JS Wilder, B Blacklock-Schuver, FT Hakim, SA Rosenberg, RE Gress, JN Kochenderfer. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 2016; 34(10): 1112–1121 https://doi.org/10.1200/JCO.2015.64.5929
pmid: 26811520
122
J Eyquem, J Mansilla-Soto, T Giavridis, SJ van der Stegen, M Hamieh, KM Cunanan, A Odak, M Gönen, M Sadelain. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543(7643): 113–117 https://doi.org/10.1038/nature21405
pmid: 28225754
S Li, N Siriwon, X Zhang, S Yang, T Jin, F He, YJ Kim, J Mac, Z Lu, S Wang, X Han, P Wang. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res 2017; 23(22): 6982–6992 https://doi.org/10.1158/1078-0432.CCR-17-0867
pmid: 28912137
125
L Kuryk, AW Møller, M Jaderberg. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. OncoImmunology 2019; 8(2): e1532763 https://doi.org/10.1080/2162402X.2018.1532763
pmid: 30713786
126
H Wang, G Kaur, AI Sankin, F Chen, F Guan, X Zang. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol 2019; 12(1): 59 https://doi.org/10.1186/s13045-019-0746-1
pmid: 31186046
127
AM Li, GE Hucks, AM Dinofia, AE Seif, DT Teachey, D Baniewicz, C Callahan, C Fasano, B McBride, V Gonzalez, F Nazimuddin, DL Porter, SF Lacey, CH June, SA Grupp, SL Maude. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. American Society of Hematology Annual Meeting. 2018. San Diego, California. Blood 2018; 132 (Supplement 1): 556 https://doi.org/10.1182/blood-2018-99-112572
128
LB John, C Devaud, CP Duong, CS Yong, PA Beavis, NM Haynes, MT Chow, MJ Smyth, MH Kershaw, PK Darcy. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19(20): 5636–5646 https://doi.org/10.1158/1078-0432.CCR-13-0458
pmid: 23873688
129
A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, MF Wu, Z Mei, A Gee, B Mehta, H Zhang, N Mahmood, H Tashiro, HE Heslop, G Dotti, CM Rooney, MK Brenner. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther 2017; 25(9): 2214–2224 https://doi.org/10.1016/j.ymthe.2017.05.012
pmid: 28602436
130
ER Suarez, K Chang, J Sun, J Sui, GJ Freeman, S Signoretti, Q Zhu, WA Marasco. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 2016; 7(23): 34341–34355 https://doi.org/10.18632/oncotarget.9114
pmid: 27145284
131
ME Prosser, CE Brown, AF Shami, SJ Forman, MC Jensen. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol 2012; 51(3-4): 263–272 https://doi.org/10.1016/j.molimm.2012.03.023
pmid: 22503210
132
J Ren, X Liu, C Fang, S Jiang, CH June, Y Zhao. Multiplex genome editing to generate universal CAR T Cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23(9): 2255–2266 https://doi.org/10.1158/1078-0432.CCR-16-1300
pmid: 27815355
133
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye, WA Lim, A Marson. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 2017; 7(1): 737 https://doi.org/10.1038/s41598-017-00462-8
pmid: 28389661
134
W Hu, Z Zi, Y Jin, G Li, K Shao, Q Cai, X Ma, F Wei. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother 2019; 68(3): 365–377 https://doi.org/10.1007/s00262-018-2281-2
pmid: 30523370
135
D Vicente, AJ Lee, CS Hall, A Lucci, JE Lee, MP Kim, MHG Katz, MW Hurd, A Maitra, AD Rhim Md, CD Tzeng. Circulating tumor cells and transforming growth factor β in resected pancreatic adenocarcinoma. J Surg Res 2019; 243: 90–99 https://doi.org/10.1016/j.jss.2019.04.090
pmid: 31170555
136
H Roca, MJ Craig, C Ying, ZS Varsos, P Czarnieski, AS Alva, J Hernandez, D Fuller, S Daignault, PN Healy, KJ Pienta. IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. J Cell Biochem 2012; 113(5): 1569–1580
pmid: 22174091
137
D Achkova, J Maher. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. Biochem Soc Trans 2016; 44(2): 333–341 https://doi.org/10.1042/BST20150245
pmid: 27068937
138
PM Siegel, J Massagué. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003; 3(11): 807–821 https://doi.org/10.1038/nrc1208
pmid: 14557817
A Gupta, S Budhu, T Merghoub. One checkpoint may hide another: inhibiting the TGFb signaling pathway enhances immune checkpoint blockade. Hepatobiliary Surg Nutr 2019; 8(3): 289–294 https://doi.org/10.21037/hbsn.2019.01.10
pmid: 31245417
SH Wrzesinski, YY Wan, RA Flavell. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13(18 Pt 1): 5262–5270 https://doi.org/10.1158/1078-0432.CCR-07-1157
pmid: 17875754
144
L Zhang, Z Yu, P Muranski, DC Palmer, NP Restifo, SA Rosenberg, RA Morgan. Inhibition of TGF-b signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 2013; 20(5): 575–580 https://doi.org/10.1038/gt.2012.75
pmid: 22972494
145
M Ostroukhova, C Seguin-Devaux, TB Oriss, B Dixon-McCarthy, L Yang, BT Ameredes, TE Corcoran, A Ray. Tolerance induced by inhaled antigen involves CD4+ T cells expressing membrane-bound TGF-β and FOXP3. J Clin Invest 2004; 114(1): 28–38 https://doi.org/10.1172/JCI200420509
pmid: 15232609
146
CC Kloss, J Lee, A Zhang, F Chen, JJ Melenhorst, SF Lacey, MV Maus, JA Fraietta, Y Zhao, CH June. Dominant-negative TGF-b receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther 2018; 26(7): 1855–1866 https://doi.org/10.1016/j.ymthe.2018.05.003
pmid: 29807781
147
ZL Chang, MH Lorenzini, X Chen, U Tran, NJ Bangayan, YY Chen. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol 2018; 14(3): 317–324 https://doi.org/10.1038/nchembio.2565
pmid: 29377003
148
S Sukumaran, N Watanabe, P Bajgain, K Raja, S Mohammed, WE Fisher, MK Brenner, AM Leen, JF Vera. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov 2018; 8(8): 972–987 https://doi.org/10.1158/2159-8290.CD-17-1298
pmid: 29880586
149
C Pangault, P Amé-Thomas, P Ruminy, D Rossille, G Caron, M Baia, J De Vos, M Roussel, C Monvoisin, T Lamy, H Tilly, P Gaulard, K Tarte, T Fest. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 2010; 24(12): 2080–2089 https://doi.org/10.1038/leu.2010.223
pmid: 20944673
150
M Todaro, Y Lombardo, MG Francipane, MP Alea, P Cammareri, F Iovino, AB Di Stefano, C Di Bernardo, A Agrusa, G Condorelli, H Walczak, G Stassi. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 2008; 15(4): 762–772 https://doi.org/10.1038/sj.cdd.4402305
pmid: 18202702
151
P Parronchi, M De Carli, R Manetti, C Simonelli, S Sampognaro, MP Piccinni, D Macchia, E Maggi, G Del Prete, S Romagnani. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992; 149(9): 2977–2983
pmid: 1401925
RJ Jackson, AJ Ramsay, CD Christensen, S Beaton, DF Hall, IA Ramshaw. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75(3): 1205–1210 https://doi.org/10.1128/JVI.75.3.1205-1210.2001
pmid: 11152493
154
J Brady, S Carotta, RP Thong, CJ Chan, Y Hayakawa, MJ Smyth, SL Nutt. The interactions of multiple cytokines control NK cell maturation. J Immunol 2010; 185(11): 6679–6688 https://doi.org/10.4049/jimmunol.0903354
pmid: 20974986
155
S Wilkie, SE Burbridge, L Chiapero-Stanke, AC Pereira, S Cleary, SJ van der Stegen, JF Spicer, DM Davies, J Maher. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 2010; 285(33): 25538–25544 https://doi.org/10.1074/jbc.M110.127951
pmid: 20562098
156
S Mohammed, S Sukumaran, P Bajgain, N Watanabe, HE Heslop, CM Rooney, MK Brenner, WE Fisher, AM Leen, JF Vera. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 2017; 25(1): 249–258 https://doi.org/10.1016/j.ymthe.2016.10.016
pmid: 28129119
157
D Abate-Daga, KH Lagisetty, E Tran, Z Zheng, L Gattinoni, Z Yu, WR Burns, AM Miermont, Y Teper, U Rudloff, NP Restifo, SA Feldman, SA Rosenberg, RA Morgan. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014; 25(12): 1003–1012 https://doi.org/10.1089/hum.2013.209
pmid: 24694017
158
BM Wolpin, EM O’Reilly, YJ Ko, LS Blaszkowsky, M Rarick, CM Rocha-Lima, P Ritch, E Chan, J Spratlin, T Macarulla, E McWhirter, D Pezet, M Lichinitser, L Roman, A Hartford, K Morrison, L Jackson, M Vincent, L Reyno, M Hidalgo. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol 2013; 24(7): 1792–1801 https://doi.org/10.1093/annonc/mdt066
pmid: 23448807
HO Smith, PS Anderson, DY Kuo, GL Goldberg, CL DeVictoria, CA Boocock, JG Jones, CD Runowicz, ER Stanley, JW Pollard. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1995; 1(3): 313–325
pmid: 9815987
M Bauzon, T Hermiston. Armed therapeutic viruses — a disruptive therapy on the horizon of cancer immunotherapy. Front Immunol 2014; 5: 74 https://doi.org/10.3389/fimmu.2014.00074
pmid: 24605114
168
S Guedan, JJ Rojas, A Gros, E Mercade, M Cascallo, R Alemany. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; 18(7): 1275–1283 https://doi.org/10.1038/mt.2010.79
pmid: 20442708
169
S Guedan, D Grases, JJ Rojas, A Gros, F Vilardell, R Vile, E Mercade, M Cascallo, R Alemany. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 2012; 19(11): 1048–1057 https://doi.org/10.1038/gt.2011.184
pmid: 22113313
170
CA Fajardo, S Guedan, LA Rojas, R Moreno, M Arias-Badia, J de Sostoa, CH June, R Alemany. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res 2017; 77(8): 2052–2063 https://doi.org/10.1158/0008-5472.CAN-16-1708
pmid: 28143835
PK Bommareddy, M Shettigar, HL Kaufman. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 2018; 18(8): 498–513 https://doi.org/10.1038/s41577-018-0014-6
pmid: 29743717
173
K Twumasi-Boateng, JL Pettigrew, YYE Kwok, JC Bell, BH Nelson. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 2018; 18(7): 419–432 https://doi.org/10.1038/s41568-018-0009-4
pmid: 29695749
174
A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, O Michielin, AJ Olszanski, J Malvehy, J Cebon, E Fernandez, JM Kirkwood, TF Gajewski, L Chen, KS Gorski, AA Anderson, SJ Diede, ME Lassman, J Gansert, FS Hodi, GV Long. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017; 170(6): 1109–1119.e10 https://doi.org/10.1016/j.cell.2017.08.027
175
J Chesney, I Puzanov, F Collichio, P Singh, MM Milhem, J Glaspy, O Hamid, M Ross, P Friedlander, C Garbe, TF Logan, A Hauschild, C Lebbé, L Chen, JJ Kim, J Gansert, RHI Andtbacka, HL Kaufman. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol 2018; 36(17): 1658–1667 https://doi.org/10.1200/JCO.2017.73.7379
pmid: 28981385
176
JF Carew, DA Kooby, MW Halterman, SH Kim, HJ Federoff, Y Fong. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001; 4(3): 250–256 https://doi.org/10.1006/mthe.2001.0448
pmid: 11545616
177
KB Stephenson, NG Barra, E Davies, AA Ashkar, BD Lichty. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 2012; 19(4): 238–246 https://doi.org/10.1038/cgt.2011.81
pmid: 22158521
178
J Li, M O’Malley, J Urban, P Sampath, ZS Guo, P Kalinski, SH Thorne, DL Bartlett. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011; 19(4): 650–657 https://doi.org/10.1038/mt.2010.312
pmid: 21266959
179
JD Dias, O Hemminki, I Diaconu, M Hirvinen, A Bonetti, K Guse, S Escutenaire, A Kanerva, S Pesonen, A Löskog, V Cerullo, A Hemminki. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 2012; 19(10): 988–998 https://doi.org/10.1038/gt.2011.176
pmid: 22071969
180
CE Engeland, C Grossardt, R Veinalde, S Bossow, D Lutz, JK Kaufmann, I Shevchenko, V Umansky, DM Nettelbeck, W Weichert, D Jäger, C von Kalle, G Ungerechts. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014; 22(11): 1949–1959 https://doi.org/10.1038/mt.2014.160
pmid: 25156126
181
P Kleinpeter, L Fend, C Thioudellet, M Geist, N Sfrontato, V Koerper, C Fahrner, D Schmitt, M Gantzer, C Remy-Ziller, R Brandely, D Villeval, K Rittner, N Silvestre, P Erbs, L Zitvogel, E Quéméneur, X Préville, JB Marchand. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. OncoImmunology 2016; 5(10): e1220467 https://doi.org/10.1080/2162402X.2016.1220467
pmid: 27853644
182
K Watanabe, Y Luo, T Da, S Guedan, M Ruella, J Scholler, B Keith, RM Young, B Engels, S Sorsa, M Siurala, R Havunen, S Tähtinen, A Hemminki, CH June. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 2018; 3(7): 99573 https://doi.org/10.1172/jci.insight.99573
pmid: 29618658
183
EK Moon, LS Wang, K Bekdache, RC Lynn, A Lo, SH Thorne, SM Albelda. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. OncoImmunology 2018; 7(3): e1395997 https://doi.org/10.1080/2162402X.2017.1395997
pmid: 29399394
184
BD Lichty, CJ Breitbach, DF Stojdl, JC Bell. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14(8): 559–567 https://doi.org/10.1038/nrc3770
pmid: 24990523
185
K Tanoue, A Rosewell Shaw, N Watanabe, C Porter, B Rana, S Gottschalk, M Brenner, M Suzuki. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res 2017; 77(8): 2040–2051 https://doi.org/10.1158/0008-5472.CAN-16-1577
pmid: 28235763
186
A Rosewell Shaw, CE Porter, N Watanabe, K Tanoue, A Sikora, S Gottschalk, MK Brenner, M Suzuki. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol Ther 2017; 25(11): 2440–2451 https://doi.org/10.1016/j.ymthe.2017.09.010
pmid: 28974431
187
J Qiao, H Wang, T Kottke, RM Diaz, C Willmon, A Hudacek, J Thompson, K Parato, J Bell, J Naik, J Chester, P Selby, K Harrington, A Melcher, RG Vile. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 2008; 15(8): 604–616 https://doi.org/10.1038/sj.gt.3303098
pmid: 18305577
188
C Cole, J Qiao, T Kottke, RM Diaz, A Ahmed, L Sanchez-Perez, G Brunn, J Thompson, J Chester, RG Vile. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11(10): 1073–1081 https://doi.org/10.1038/nm1297
pmid: 16170322
189
H VanSeggelen, DG Tantalo, A Afsahi, JA Hammill, JL Bramson. Chimeric antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther Oncolytics 2015; 2: 15014 https://doi.org/10.1038/mto.2015.14
pmid: 27119109
190
AC Parente-Pereira, LM Whilding, N Brewig, SJ van der Stegen, DM Davies, S Wilkie, MC van Schalkwyk, S Ghaem-Maghami, J Maher. Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin. J Immunol 2013; 191(5): 2437–2445 https://doi.org/10.4049/jimmunol.1301119
pmid: 23898037
191
P Muranski, A Boni, C Wrzesinski, DE Citrin, SA Rosenberg, R Childs, NP Restifo. Increased intensity lymphodepletion and adoptive immunotherapy — how far can we go? Nat Clin Pract Oncol 2006; 3(12): 668–681 https://doi.org/10.1038/ncponc0666
pmid: 17139318
192
KJ Curran, S Margossian, NA Kernan, LB Silverman, DA Williams, NN Shukla, R Kobos, C Forlenza, P Steinherz, S Prockop, F Boulad, B Spitzer, MI Cancio, JJ Boelens, AL Kung, VZ Szenes, J Park, CS Sauter, G Heller, X Wang, B Senechal, RJ O’Reilly, I Riviere, M Sadelain, RJ Brentjens. Toxicity and response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. Blood 2019; 134(26): 2361–2368 https://doi.org/10.1182/blood.2019001641
193
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, SR Riddell, DG Maloney, CJ Turtle. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 2019; 134(7): 636–640 https://doi.org/10.1182/blood.2019000905
pmid: 31648294
194
AR Haas, JL Tanyi, MH O’Hara, WL Gladney, SF Lacey, DA Torigian, MC Soulen, L Tian, M McGarvey, AM Nelson, CS Farabaugh, E Moon, BL Levine, JJ Melenhorst, G Plesa, CH June, SM Albelda, GL Beatty. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther 2019; 27(11): 1919–1929 https://doi.org/10.1016/j.ymthe.2019.07.015
pmid: 31420241
195
JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, M Stetler-Stevenson, D Salem, C Yuan, S Pavletic, JA Kanakry, SA Ali, L Mikkilineni, SA Feldman, DF Stroncek, BG Hansen, J Lawrence, R Patel, F Hakim, RE Gress, JN Kochenderfer. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018; 36(22): 2267–2280 https://doi.org/10.1200/JCO.2018.77.8084
pmid: 29812997
196
WY Zhang, Y Liu, Y Wang, J Nie, YL Guo, CM Wang, HR Dai, QM Yang, ZQ Wu, WD Han. Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. Gene Ther 2018; 25(3): 198–204 https://doi.org/10.1038/s41434-017-0001-8
pmid: 29599530
197
K Feng, Y Liu, Y Guo, J Qiu, Z Wu, H Dai, Q Yang, Y Wang, W Han. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 2018; 9(10): 838–847 https://doi.org/10.1007/s13238-017-0440-4
pmid: 28710747
198
RJ Brentjens, I Rivière, JH Park, ML Davila, X Wang, J Stefanski, C Taylor, R Yeh, S Bartido, O Borquez-Ojeda, M Olszewska, Y Bernal, H Pegram, M Przybylowski, D Hollyman, Y Usachenko, D Pirraglia, J Hosey, E Santos, E Halton, P Maslak, D Scheinberg, J Jurcic, M Heaney, G Heller, M Frattini, M Sadelain. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118(18): 4817–4828 https://doi.org/10.1182/blood-2011-04-348540
pmid: 21849486
T Weiss, M Weller, M Guckenberger, CL Sentman, P Roth. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res 2018; 78(4): 1031–1043 https://doi.org/10.1158/0008-5472.CAN-17-1788
pmid: 29222400
202
C DeSelm, ML Palomba, J Yahalom, M Hamieh, J Eyquem, VK Rajasekhar, M Sadelain. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther 2018; 26(11): 2542–2552 https://doi.org/10.1016/j.ymthe.2018.09.008
pmid: 30415658
203
C Qu, N Ping, Q Wu, L Kang, F Xia, L Yu, D Wu, Z Jin. Radiotherapy priming chimeric antigen receptor T cell therapy is a safe and promising approach in relapsed/refractory diffuse large B cell lymphoma patients with high tumor burden. Blood 2018; 132(Suppl 1): 2961
204
TT Smith, HF Moffett, SB Stephan, CF Opel, AG Dumigan, X Jiang, VG Pillarisetty, SPS Pillai, KD Wittrup, MT Stephan. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest 2017; 127(6): 2176–2191 https://doi.org/10.1172/JCI87624
pmid: 28436934
205
SA Bencherif, R Warren Sands, OA Ali, WA Li, SA Lewin, TM Braschler, TY Shih, CS Verbeke, D Bhatta, G Dranoff, DJ Mooney. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun 2015; 6(1): 7556 https://doi.org/10.1038/ncomms8556
pmid: 26265369
206
J Kim, WA Li, Y Choi, SA Lewin, CS Verbeke, G Dranoff, DJ Mooney. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol 2015; 33(1): 64–72 https://doi.org/10.1038/nbt.3071
pmid: 25485616
LC Bailey-Downs, JE Thorpe, BC Disch, A Bastian, PJ Hauser, T Farasyn, WL Berry, RE Hurst, MA Ihnat. Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One 2014; 9(5): e98624 https://doi.org/10.1371/journal.pone.0098624
pmid: 24878664
209
F Zhang, SB Stephan, CI Ene, TT Smith, EC Holland, MT Stephan. Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res 2018; 78(13): 3718–3730 https://doi.org/10.1158/0008-5472.CAN-18-0306
pmid: 29760047
210
D Hambardzumyan, NM Amankulor, KY Helmy, OJ Becher, EC Holland. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2009; 2(2): 89–95 https://doi.org/10.1593/tlo.09100
pmid: 19412424
211
M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, L Mechtler, SA Goldlust, F Iwamoto, J Drappatz, DM O’Rourke, M Wong, MG Hamilton, G Finocchiaro, J Perry, W Wick, J Green, Y He, CD Turner, MJ Yellin, T Keler, TA Davis, R Stupp, JH Sampson; ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017; 18(10): 1373–1385 https://doi.org/10.1016/S1470-2045(17)30517-X
pmid: 28844499
212
N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, C Robertson, TL Gray, O Diouf, A Wakefield, A Ghazi, C Gerken, Z Yi, A Ashoori, MF Wu, H Liu, C Rooney, G Dotti, A Gee, J Su, Y Kew, D Baskin, YJ Zhang, P New, B Grilley, M Stojakovic, J Hicks, SZ Powell, MK Brenner, HE Heslop, R Grossman, WS Wels, S Gottschalk. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 2017; 3(8): 1094–1101 https://doi.org/10.1001/jamaoncol.2017.0184
pmid: 28426845